AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01238120 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 200mg BID and 8 hours apart
Study NCT04453111 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placenta-derived MMSCs
Description: Cryopreserved placenta-derived multipotent mesenchymal stem / stromal cells
Study NCT04453111 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bone marrow-derived MMSCs
Description: Cryopreserved bone marrow-derived multipotent mesenchymal stem / stromal cells
Study NCT04453111 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyalgan 20 mg in 2 ML Prefilled Syringe
Description: Hyaluronic Acid 20 mg
Study NCT04453111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyalgan 20 mg in 2 ML Prefilled Syringe
Description: Hyaluronic Acid 20 mg
Study NCT03934762 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: A placebo solution that will not include aloe vera will be applied on the quadriceps of one of the lower limbs.
Study NCT03934762 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Natural Aloe Vera
Description: Natural aloe vera solution including peel and leaf from aloe will be applied on the the quadriceps of one of the lower limbs.
Study NCT01659905 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Singulair
Description: 5 mg Chewable Tablet
Study NCT01901783 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: With primary closure
Description: A cancellous block allograft will be placed for ridge augmentation and covered with a barrier membrane. The soft tissue will be primarily closed over the membrane.
Study NCT01901783 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Without primary closure
Description: A cancellous block allograft will be placed for ridge augmentation and covered with a barrier membrane. The soft tissue will not be primarily closed over the membrane.
Study NCT03429634 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Balloon-Stent Kissing technique
Description: All patients underwent coronary angiogram that confirmed true bifurcation lesions, and received PCI treatment,Balloon-Stent Kissing Technique (BSKT)for the interventional treatment of coronary bifurcation lesion
Study NCT03429634 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Balloon-Stent Kissing technique
Description: All patients underwent coronary angiogram that confirmed true bifurcation lesions, and received PCI treatment,Balloon-Stent Kissing Technique (BSKT)for the interventional treatment of coronary bifurcation lesion
Study NCT03429634 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Jailed Wire technique
Description: All patients underwent coronary angiogram that confirmed true bifurcation lesions, and received PCI treatment, Jailed Wire technique(JWT) for the interventional treatment of coronary bifurcation lesion
Study NCT03429634 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Jailed Wire technique
Description: All patients underwent coronary angiogram that confirmed true bifurcation lesions, and received PCI treatment, Jailed Wire technique(JWT) for the interventional treatment of coronary bifurcation lesion
Study NCT04325256 — intervention group
Intervention type: PROCEDURE
Intervention: Manipal ultrasound scoring system
Description: length of the cervix from the internal to external os, presence or absence of funneling and if present width and length of funneling at internal os were measured. Distance between presenting part to external os will be measured and position of the cervix i.e. whether curved or straight will also noted.
Study NCT04325256 — intervention group
Intervention type: PROCEDURE
Intervention: Levine scoring system
Description: maternal height, parity, body-mass index (BMI) at delivery and the results of modified Bishop's score in calculation of probability of CS
Study NCT02465320 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: COL-1077
Description: single dose of 150mg lidocaine (10%w/w) administered by intravaginal insertion
Study NCT02465320 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single dose of bioadhesive gel administered by intravaginal insertion
Study NCT01286922 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Behavioral: exercise
Description: Specific Aim: We will identify, recruit, assess, and randomly assign 42 sedentary, overweight-obese individuals who are at risk for pre-diabetes to an AER or INT training group in order to test the hypothesis:~• Individuals randomized to INT will have greater improvements in insulin sensitivity than individuals assigned to traditional AER.~Secondary Aim: We will measure maximal cardiorespiratory fitness (VO2max/peak) in order to test the hypothesis:~• Individuals randomized to the INT group will have a greater improvement in VO2max/peak than individuals in traditional AER group.
Study NCT01286922 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Behavioral: exercise
Description: Specific Aim: We will identify, recruit, assess, and randomly assign 42 sedentary, overweight-obese individuals who are at risk for pre-diabetes to an AER or INT training group in order to test the hypothesis:~• Individuals randomized to INT will have greater improvements in insulin sensitivity than individuals assigned to traditional AER.~Secondary Aim: We will measure maximal cardiorespiratory fitness (VO2max/peak) in order to test the hypothesis:~• Individuals randomized to the INT group will have a greater improvement in VO2max/peak than individuals in traditional AER group.
Study NCT04605861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: Liraglutide Injection, once a day, injected subcutaneously on the sites of abdomen, thigh or upper arm. The initial dose of Liraglutide Injection will be 0.6 mg per day. The dose is escalated every one to two weeks to reduce the gastrointestinal symptoms. At Week 7, the dose is increased to 3.0 mg per day. For the subjects who are not able to tolerate the target dose of 3.0 mg,the dose is reduced to 2.4 mg a day and escalated to the dose to 3.0 mg within two weeks. If the subjects are still unable to tolerate this dose (3.0 mg), the treatment is terminated.
Study NCT04605861 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Injection, once a day, injected subcutaneously on the sites of abdomen, thigh or upper arm. The initial dose of Placebo Injection will be 0.6 mg per day. The dose is escalated every one to two weeks to reduce the gastrointestinal symptoms. At Week 7, the dose is increased to 3.0 mg per day. For the subjects who are not able to tolerate the target dose of 3.0 mg,the dose is reduced to 2.4 mg a day and escalated to the dose to 3.0 mg within two weeks. If the subjects are still unable to tolerate this dose (3.0 mg), the treatment is terminated.
Study NCT01838720 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: zero ischemia laparoscopic RFA assisted TE
Study NCT01838720 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ischemia
Description: conventional laparoscopic partial nephrectomy
Study NCT02496546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 32731 cream
Description: Applied for 3 weeks
Study NCT02496546 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LEO 32731 cream vehicle
Description: Applied for 3 weeks
Study NCT01354860 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moxibustion treatment plus usual care
Description: Treatment group received moxibustion treatment three times a week for 4 consecutive weeks, totally 12 sessions of treatment in addition to usual care to manage their knee OA.~Moxibustion points include six local acupuncture points on affected knee joint. Up to two additional tender points will be allowed, if necessary. If participants feel knee pain on both knee joints, study practitioners will provide treatment on both knee.~We will use smokeless indirect moxibustion made of wormwood with a diameter of 1.9 centirmeter and a length of 2.1 centimeter in a cylindrical form for this study (Haitnim Bosung Inc, Korea). Free participant-practitioner interaction will be allowed during the treatment session. Expected total time of each treatment session will be 40 - 60 minutes.
Study NCT01354860 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Usual care alone group
Description: Usual care alone group can receive or use any kind of treatment other than moxibustion treatment provided as study intervention, which includes surgery, conventional medication, physical treatment, acupuncture, herbal medicine, over-the-counter drugs and other active treatment. This also applies to the moxibustion treatment group.~Education material of information on knee osteoarthritis and current management option and self-exercise sheet with a yoga-mat to enhance regular exercise will be provided in both groups at baseline.
Study NCT01601145 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: consumption of lozenges
Description: Each subject two lozenges a day for 6 weeks
Study NCT01601145 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: consumption of lozenges
Description: Each subject two lozenges a day for 6 weeks
Study NCT03414593 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided popliteal sciatic nerve block with 0.2% ropivcaine
Description: Ultrasound guided popliteal sciatic nerve block with 0.2% ropivacaine 20ml
Study NCT03414593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ultrasound guided popliteal sciatic nerve block with 0.2% ropivcaine
Description: Ultrasound guided popliteal sciatic nerve block with 0.2% ropivacaine 20ml
Study NCT02478047 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: only antiemetic (Ramosetron, Tropisetron and dexamethasone)
Description: The control group will receive standard antiemetic alone. Standard antiemetic for all groups is based on American Society of Clinical Oncology clinical practice guideline. 5-hydroxytryptamine-3 (5-HT3) antagonist (Ramosetron, Tropisetron) and dexamethasone are supplied from the first day of chemotherapy, and lasting for 3-5 days.And plus antiemetic drug as the comparator group.
Study NCT02478047 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Matching points ST36+CV12 plus antiemetic drug
Description: Choose both Zusanli(ST36) and Zhongwan point(CV12). Manipulating until achieving a de Qi sensation, then the needles are connected through a electro-acupuncture apparatus, the positive poles are linked to the needle, and the reference poles are located near the acupoint about 1cm with a paster. Frequency 10Hz,the intensity of stimulation is adjusted according to the patient's tolerance, and the electric current is less than 10mA. The operation lasts for 30 min. The treatment is scheduled to occur within 30min-60min before chemotherapy infusion for 4 days.And plus antiemetic drug as the comparator group.
Study NCT02478047 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Matching points PC6+CV12 plus antiemetic drug
Description: Choose both Neiguan(PC6) and Zhongwan point(CV12). Manipulating until achieving a de Qi sensation, then the needles are connected through a electro-acupuncture apparatus, the positive poles are linked to the needle, and the reference poles are located near the acupoint about 1cm with a paster. Frequency 10Hz,the intensity of stimulation is adjusted according to the patient's tolerance, and the electric current is less than 10mA. The operation lasts for 30 min. The treatment is scheduled to occur within 30min-60min before chemotherapy infusion for 4 days.And plus antiemetic drug as the comparator group.
Study NCT02478047 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Matching points CV13+CV12 plus antiemetic drug
Description: Choose both Shangwan(CV13) and Zhongwan point(CV12). Manipulating until achieving a de Qi sensation, then the needles are connected through a electro-acupuncture apparatus, the positive poles are linked to the needle, and the reference poles are located near the acupoint about 1cm with a paster. Frequency 10Hz,the intensity of stimulation is adjusted according to the patient's tolerance, and the electric current is less than 10mA. The operation lasts for 30 min. The treatment is scheduled to occur within 30min-60min before chemotherapy infusion for 4 days.And plus antiemetic drug as the comparator group.
Study NCT03872674 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: high-flow humidified oxygen-delivery system (OptiFlow THRIVE)
Description: stand oxygenation arm will receive oxygen at 5 L/min via nasal cannula, while Optiflow THRIVE arm will receive oxygen at 50 L/min via Optiflow THRIVE during the procedure.
Study NCT03934762 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aloe vera soup
Description: Aloe vera solution including aloe vera soup will be applied on the the quadriceps of one of the lower limbs.
Study NCT04290637 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cold-water sea swimming
Description: Continue sea swimming for 4-6 weeks
Study NCT04290637 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No cold-water sea swimming
Description: Discontinue sea swimming for 4-6 weeks
Study NCT03882918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OV101
Description: Each subject will be titrated to his or her maximal tolerated daily dose, up to a maximum daily dose of 15 mg at bedtime.
Study NCT01931046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ad5-SGE-REIC/Dkk3
Description: Ad5-SGE-REIC/Dkk-3, was designed to increase intracellular production REIC protein. The adenovirus vector is a transport mechanism to infuse the REIC protein into the cell providing a temporary transfusion of protein that induces apoptosis in target cancer cells, but does not appear to have a significant effect on normal tissues.
Study NCT03050164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib Tablet 250mg of Hunan Kelun
Description: Single dose of Gefitinib Tablet 250mg of Hunan Kelun was administered after a 10-hour overnight fast.
Study NCT03050164 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gefitinib Tablet 250mg of Hunan Kelun
Description: Single dose of Gefitinib Tablet 250mg of Hunan Kelun was administered after a 10-hour overnight fast.
Study NCT03050164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iressa® Tablet 250mg of AZN
Description: Single dose of Iressa® Tablet 250mg of AZN was administered after a 10-hour overnight fast.
Study NCT03050164 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iressa® Tablet 250mg of AZN
Description: Single dose of Iressa® Tablet 250mg of AZN was administered after a 10-hour overnight fast.
Study NCT02521480 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Transcranial Magnetic Stimulation
Description: TMS is a non-invasive treatment. During TMS treatment, a coil, which creates a magnetic field, will be placed on the left prefrontal area of the head. Active TMS will stimulate for 4 seconds, pause for 26 seconds, and repeat this for approximately 40 minutes. There will be a total of 3000 pulses during treatment. We expect TMS to decrease pain and depression. In order to find out if this is true, we will compare real TMS with sham (inactive) TMS.This will allow us to decide if active TMS is successful because of electrical stimulation, or because of the support, concern, and understanding of the research team.
Study NCT02521480 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Magnetic Stimulation
Description: Inactive treatment (simulation of active TMS)
Study NCT03726476 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient centered pre-op education
Description: To implement a patient centered education intervention to evaluate post-op narcotic use.
Study NCT03202030 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immediate dentoalveolar restoration
Description: Block of bone removed from the tuber and placed in the buccal resorption of the socket together with an immediate implant
Study NCT03726476 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: routine preop education
Description: To implement routine patient education intervention to evaluate post-op narcotic use.
Study NCT04262934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol 100.000 UI administration
Description: One oral Administration - Every month
Study NCT04262934 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No vitamin D administration
Description: No vitamin D administration
Study NCT01278953 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter ablation to treat paroxysmal atrial fibrillation
Description: A pulmonary vein isolation procedure will be performed using radiofrequency ablation.
Study NCT01278953 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Catheter ablation to treat paroxysmal atrial fibrillation
Description: A pulmonary vein isolation procedure will be performed using radiofrequency ablation.
Study NCT02544789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: Clofarabine (Betta Pharmaceuticals Co., Ltd, Zhejiang, China) was administered intravenously at 52 mg/m2 over 2 hours daily for 5 consecutive days. During the first two induction cycles, patients who did not achieve an objective response were taken off the study, and responsive patients continued to receive consolidation for a maximum 11 cycles if non-hematological toxicity was grade 2 or less.
Study NCT00549718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurasidone HCl
Description: Once daily
Study NCT04785729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Almonertinib combine with Pyrrolitinib
Description: 110mg,qd Almonertinib+（240mg/320mg/400mg）,qd Pyrrolitinib
Study NCT00549718 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lurasidone HCl
Description: Once daily
Study NCT03620747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab SAR231893 (REGN668)
Description: Pharmaceutical form: prefilled syringes~Route of administration: subcutaneous
Study NCT03999684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tretinoin
Description: ATRA control normal cell growth, cell differentiation (the normal process of making cell different from each other), and cell death during embryonic development and in certain tissues later in life. Retinoids effects on the cells are controlled by receptors on the nucleus of each cell (nuclear receptors)
Study NCT02514330 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interval Training at 1% incline
Description: Six stimuli were performed to exhaustion. The vertical drop jump strategy (height and kinematics) served to establish the magnitude of the concurrent effect
Study NCT02514330 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interval Training at 10% incline
Description: Six stimuli were performed to exhaustion. The vertical drop jump strategy (height and kinematics) served to establish the magnitude of the concurrent effect.
Study NCT05492279 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: sheep ghee
Description: natural sheep ghee, given to patient in a commercial box and intervention group 10 gr per day from sheep ghee
Study NCT03558724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab-IRDye800CW
Description: Intravenous administration of 4.5, 10 or 25 mg of Bevacizumab-IRDye800CW prior to the endoscopic procedure
Study NCT03202030 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Demineralized bovine bone
Description: Block of demineralised bovine bone placed in the buccal resorption of the socket together with an immediate implant
Study NCT00676507 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lucanix™
Description: Treatment Arm: Subjects receive Lucanix™ (belagenpumatucel-L) intradermally (ID) once monthly for 18 months and then once at 21 and 24 months in the absence of disease progression or unacceptable toxicity.
Study NCT00676507 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Control Arm: Subjects receive placebo ID once monthly for 18 months and then once at 21 and 24 months in the absence of disease progression or unacceptable toxicity.
Study NCT02203149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir
Description: One or two 50 mg tablets (depending on randomization) taken orally once daily for 12 weeks.
Study NCT02203149 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Grazoprevir
Description: One or two 50 mg tablets (depending on randomization) taken orally once daily for 12 weeks.
Study NCT02203149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elbasvir
Description: One 50 mg tablet taken orally once daily for 12 weeks.
Study NCT02203149 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Elbasvir
Description: One 50 mg tablet taken orally once daily for 12 weeks.
Study NCT02203149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Grazoprevir
Description: One tablet of placebo matched to grazoprevir, taken orally once daily for 12 weeks.
Study NCT02203149 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Grazoprevir
Description: One tablet of placebo matched to grazoprevir, taken orally once daily for 12 weeks.
Study NCT02203149 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Elbasvir
Description: One tablet of placebo matched to elbasvir, taken orally once daily for 12 weeks.
Study NCT01766648 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Far Cortical locking screw fixation
Description: Standard screw fixation
Study NCT01766648 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard screw fixation